TREAT OA
Translational Research in Europe – Applied Technologies for Osteoarthritis
| Coordinatore | KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.treatoa.eu/ |
| Totale costo | 16˙673˙604 € |
| EC contributo | 11˙924˙660 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-01-01 - 2013-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | coordinator | 0.00 |
| 2 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 0.00 |
| 3 |
ARCARIOS
Organization address
address: AGORALAAN A BIS contact info |
BE (DIEPENBEEK) | participant | 0.00 |
| 4 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 0.00 |
| 5 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 0.00 |
| 6 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 0.00 |
| 7 |
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
Organization address
address: KLOVENIERSBURGWAL 29 HET TRIPPENHUIS contact info |
NL (AMSTERDAM) | participant | 0.00 |
| 8 |
SYNARC SAS
Organization address
address: RUE DE MONTBRILLANT 16 contact info |
FR (LYON) | participant | 0.00 |
| 9 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 10 |
TiGENIX NV
Organization address
address: RESEARCHPARK HAASRODE 1724 ROMEINSE STRAAT 12/2 contact info |
BE (LEUVEN) | participant | 0.00 |
| 11 |
UNIVERSITY OF IOANNINA
Organization address
address: "LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON" contact info |
EL (IOANNINA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'TREAT-OA will address the need for better treatment and diagnostics for osteoarthritis (OA) - the most common cause of disability in Europe. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, costs of therapeutic trials and the development of disease modifying drugs. TREAT-OA represents a large-scale collaborative, integrated, trans-disciplinary project utilising a resource of 28,000 OA phenotyped subjects with available genome-wide association scan data as well as leading basic science laboratories and technologies. This is the largest study of its kind that will address the generalisability and utility of genetic and biochemical risk factors throughout the EU. The key objectives of TREAT-OA are to: 1 Identify genes and biochemical markers consistently associated with risk and progression of OA 2 Use such genes to further our understanding of the molecular pathways involved in disease aetiology 3 Analyze pathways to identify targets for pharmacological intervention 4 Develop transgenic animal laboratory OA model systems . 5 Develop a panel of genetic and biochemical diagnostics for risk and progression of OA 6 Disseminate results from this extensive research at large and use results and technologies for training within the EU TREAT-OA will help develop European clinical and scientific excellence in the diagnosis and treatment of OA. The novel pathways in disease aetiology discovered will translate into novel drug targets and protein therapeutics for OA. The development of in vitro and in vivo assays will provide a comprehensive technology platform enabling the discovery and development of disease modifying drugs for OA. TREAT-OA will also make a major impact on the disease via a diagnostic panel of genes and biochemical markers for selecting severe cases and rapidly progressing individuals.'